Navigation Links
CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings

en from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Glenn Schulman, Pharm.D.

    Director of Investor Relations

    

    (888) 436-6642


    CRGN-P
gschulman@curagen.com

CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations, CuraGenCorporation, +1-888-436-6642, gschulman@curagen.com

Web site: http://www.curagen.com/http://www.topotarget.com/

Ticker Symbol: (NASDAQ-NMS:CRGN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/16/2008)...l Mechanism May Offer Novel Approach to Blood ...EANS, May 16 /- Pharmacopei...d development of novel small,molecule therapeutics...s,Dual Acting Receptor Antagonist (DARA), showed s... in a Phase 2a study in patients with mild to,mode...
(Date:5/15/2008)... 15 /- Patients with breast or,colore...s, can expect,further treatment advances with Avas...) following new data that is being presented at th...) annual meeting in Chicago at,the end of May. Aro... which,is the premier event for cancer therapy wor...
(Date:5/15/2008)...t ASCO Showed Acceptable Tolerability Profile, ...pathy, WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ ...ulin mesylate (E7389) demonstrated activity in a,h... advanced or metastatic,breast cancer, according t...l. The study also suggests that eribulin mesylate ...
(Date:5/15/2008)...emonstrated in Blacks, Hispanics/Latinos, People ...s, PARSIPPANY, N.J., May 15 /- Daiic...ed at the American Society of,Hypertension,s Twent...ew,Orleans demonstrated that the powerful combinat...omil) safely and effectively helped,patients acros...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Media Invitation Annual General and Special Meeting of Shareholders of Haemacure 16206 1Media Invitation Annual General and Special Meeting of Shareholders of Haemacure 16206 2Navigenics 28TM 29 Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 1702 1Navigenics 28TM 29 Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments 1702 2Molecular Vision and Acrongenomics Unable to Reach Agreement on the Acquisition of Molecular Vision 4447 1Study Shows the Personal Touch Is Key to Maintaining Weight Loss 16201 1Study Shows the Personal Touch Is Key to Maintaining Weight Loss 16201 2
(Date:5/16/2008)...delines quickly disseminated to community physicia...thDay News) -- Partnerships between major academic...k and effective way to spread cancer treatment adv...in Philadelphia. , Most new cancer treatments a...er care is provided at community hospitals, noted ...
(Date:5/16/2008)...in some early stage cases makes therapy of little ...ay 16 (HealthDay News) -- Colon cancer patients wi...receive chemotherapy. In fact, not only does chemo... actually harm them, a new study found. , "If yo...hen you should not be treated with chemotherapy. S...
(Date:5/16/2008)...a., May 16 /PRNewswire-USNewswire/ -- The Centers ...gency for Toxic Substances and,Disease Registry (A...,Health Improvement Award for 2008. Since its 1999... Stockpile (DSNS) in the CDC Coordinating Office,f...with LMI,s Health,Systems Management group, supple...
(Date:5/16/2008)... scheduled for Pittsburgh Zoo & PPG Aquarium for M...r Life, the Medicare product,of UPMC Health Plan, ...ual,National Senior Health & Fitness Day, which ha....", National Senior Health & Fitness Day is sched...will serve as host for three events in,Pennsylvani...
Breaking Medicine News(10 mins):Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2Health News:UPMC for Life is Pennsylvania Sponsor for National Senior Health & Fitness Day 2
...lth Service reform said that local hospitals shoul...ble.// Andrew Foster, the outgoing workforce direc...s ingrained practices have to undergo a change. Th...atients greater choice and allowing more hospitals...
...thwestern state of Sokoto has killed at least five...igeria.// The cases of Cerebra Spinal Meningitis ...t area. Initial figures reveal that at least 14 pe...break of measles has also been reported in the are...
...ing to India and desperate to do so. It is not to ...hes// of Goa but to rid themselves of the extra fl...Amir a Bangladesh-born American and Hardeep a Sikh...e to get in shape. The hub of laparoscopic surgeri...
...ope Benedict XVI’s intention of soliciting a repor... benefits of condom use //in exceptional cases, su...ed with H.I.V, with a view to protect life within ...ve commended the efforts of the church to have add...
Other Medicine News:Health News:India is the "IT" destination for obesity cure: med tourism 2
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
The Guidant Flextend lead is a steroid-eluting, transvenous pace/sense lead with an extendable/retractable active-fixation helix. The extendable/retractable helix design offers various lead placement
The Vitatron Impulse II lead series are silicon rubber endocardial leads specifically designed to extend the longevity of the pacemaker system by providing energy efficient pacing. The high impedance
The RZ is a small lead body profile implantable unipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model).
Medicine Products: